NCT05982873 2026-02-06
Expanded Access to Telisotuzumab Adizutecan
AbbVie
Available
Clinical Trials
12 trialsNCT05064306 2025-08-01
131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults
Memorial Sloan Kettering Cancer Center
No longer available
NCT03874455 2024-03-22
Tazemetostat Expanded Access Program for Adults With Solid Tumors
Ipsen
No longer available
NCT03914872 2024-03-12
Expanded Access Neoantigen Vaccine in Solid Tumors
Washington University School of Medicine
No longer available
NCT06188975 2024-01-03
Expanded Access to ABBV-CLS-484
Calico Life Sciences LLC
Available
NCT05107193 2022-11-08
Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors)
Boehringer Ingelheim
No longer available
NCT05511350 2022-10-18
Expanded Access Protocol for Subjects With Relapsed or Refractory Advanced Solid Tumors Receiving TJ210001
I-Mab Biopharma US Limited
No longer available
NCT02354612 2021-02-15
Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial
Tracon Pharmaceuticals Inc.
No longer available
NCT04644107 2020-11-25
Expanded Access for Marizomib
Celgene
No longer available
NCT01151930 2020-11-17
Long-Term Compassionate Use Study for Continued Administration of SCB01A-01
SynCore Biotechnology Co., Ltd.
No longer available
NCT03702036 2020-04-13
Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma
GlaxoSmithKline
No longer available
NCT00040625 2007-03-15
ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.
Eli Lilly and Company
Approved for marketing